The state of Connecticut currently has 37 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NCT04305444
Recruiting
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2023
Locations: Yale - Smillow Cancer Hospital, New Haven, Connecticut
Conditions: Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
Register for Updates